通过向一个Ca2+依赖的全结合位来抑制丁氨酸减弱酶 (PAD1-4)
Leslie A Dakin1, Li Xing1, Justin Hall2
1Medicine Design, Pfizer Inc, Cambridge, MA, USA.
研究人员确定了Peptidylarginine deiminases (PAD1-4) 上的一个常见的全位,以开发非共价抑制剂. 这一发现为向PAD酶提供了一种新的策略,这些酶与类风湿性关节炎等疾病有关.
科学领域:
- 生物化学 生化学
- 酶学 是一种酶学.
- 药物发现 药物发现 药物发现
背景情况:
- 丁丁氨酸减小酶 (PAD1-4) 催化蛋白质素化,这种变化与类风湿性关节炎,神经退行性疾病和癌症有关.
- 目前用于PAD酶的抑制剂主要是共价基质类似物,对更广泛的家族抑制的选择有限.
研究的目的:
- 在PAD1-4中识别一个共同的全结合口袋,用于开发强效的非共价抑制剂.
- 描述一种针对这种全位的新型抑制剂,并评估其对多个PAD异酶的疗效.
主要方法:
- 基于干的虚拟查,以确定潜在的PAD4抑制剂.
- 表面等离子体共振 (SPR) 确认目标结合并评估结合动力学.
- 同晶体结构分析以阐明结合模式和抑制机制.
- 试验室试验评估抑制中性粒细胞中PAD异酶和蛋白质素化.
主要成果:
- 鉴定了PAD1-4.4常见的新型全结合口袋.
- 一个虚拟屏幕产生了一种PAD4抑制剂,该抑制剂与已知的配体无竞争性结合.
- 共同晶体结构显示,该抑制剂稳定了PAD4的催化不活性,缺的形状.
- 基于全位的合理设计的连接体强烈抑制所有四个PAD异酶,并减少中性粒细胞中的蛋白质素化.
结论:
- 在PAD1-4上有一个新的,常见的全位,使强大的非共价抑制剂的发展成为可能.
- 这一策略为与异常PAD活动相关的疾病提供了有前途的治疗方法.
- 开发的抑制剂在PAD异酶和细胞环境中表现出广泛的有效性.
更多相关视频
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Inhibition of Cdk Activity
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
The JAK-STAT Signaling Pathway
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
